The present technology describes the use of two enzymes (angiotensin-converting enzyme and/or angiotensin-converting enzyme 2) as fecal biomarkers, using them or a composite of both to assess, diagnose or monitor inflammatory bowel disease, as well as a response to treatment and intestinal health. The invention includes the sequencing of the fecal enzymes, the production and use of target antibodies against them, and a kit based on the detection of those enzymes with the antibodies.
Background:
Nowadays, the diagnosis and monitoring of inflammatory bowel disease rely on patient interviews, routine clinical analysis and invasive procedures, like colonoscopies, biopsies and blood samples. Also, dysbiosis is emerging as a health imbalance. Recently, fecal biomarkers are emerging as a more convenient alternative.
Benefits:
Potential comercial use/applications:
A kit for non-invasive fecal biomarker of inflammatory bowel disease and other pathophysiological conditions and for monitoring intestinal health.
U.Porto Inovação was established in 2004 to support the University’s innovation value chain by facilitating the transfer of knowledge and strengthening the relationship between the University and businesses. With over 20 years of experience, U.Porto Innovation focuses its activities on research at the University, entrepreneurship within the academic community and U.Porto’s growing connections with industry.
Create your free account to connect with University of Porto and thousands of other innovative organizations and professionals worldwide
Send a request for information
to University of Porto
Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.
Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support
